A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2018-10-09
Target enrollment:
Participant gender:
Summary
This study is designed to establish biosimilarity of SB8, a proposed biosimilar product of
bevacizumab, to EU-sourced bevacizumab, in patients with metastatic or recurrent non-squamous
non-small cell lung cancer (NSCLC).